Kornimate/medical-research-clean huggingface dataset:
a study to test the safety, amount and effects of pf-06282999 in healthy overweight adults and a study to test the effects of pf-06282999 on the amount of the approved drug, midazolam, in healthy adults

Conditions: Healthy

Summary: part a of the study will test the safety, the amount of drug in the body, and effects of the drug in the body after multiple doses. this will be conducted in healthy overweight adults. part b of the study will test the effects of multiple doses of the investigational drug on the amount of midazolam, an approved drug, in healthy adults.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ecg and clinical laboratory tests). women must be of non childbearing potential. * body mass index (bmi) of 27.0 to 35.0 kg/m2 (part a) or 17.5 to 30.5 kg/m2 (part b); and a total body weight \>50 kg (110 lbs). exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including clinically significant drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * subject with any contraindication to midazolam according to the country specific labeling or subject with previous intolerance or allergy to benzodiazepines (applicable to part b of study only). * subjects who were enrolled in part a are excluded from participation in part b of this study. * subjects who have previously participated in a study with pf-06282999.
effects of omega-3 epa/dha for soldiers at risk for mood disorders

Conditions: Mood Disorders; Depression; Combat Disorders; Stress Disorders

Summary: stress-related disorders are among the most prevalent and expensive medical consequences of participation in military operations. omega-3 fatty acids epa/dha derived from fish oil are known to benefit both neuronal development in the young, and cognition and mood in various populations. it is possible that soldiers receiving omega-3 epa/dha will exhibit significantly higher cognitive performance, better affect/mood state, and less combat stress symptomatology compared to the placebo after 12 weeks of supplementation. a goal would be to reduce the prevalence of combat stress injuries in military personnel.


Eligibility criteria:
inclusion criteria: * us army deployed personnel * score on a mood questionnaire exclusion criteria: * currently consume omega-3 fish oil supplements * are currently taking antidepressant or other medications for psychiatric purposes * pregnant * known fish or shellfish allergy

Keywords: mood disorders depression combat disorders stress disorders fatty acids, omega-3 military personnel docosahexaenoic acids/*therapeutic use eicosapentaenoic acid/*therapeutic use
collecting and storing samples of blood from patients with pancreatic cancer and healthy participants

Conditions: Pancreatic Cancer

Summary: rationale: collecting and storing samples of blood from patients with cancer and healthy participants to test in the laboratory may help the study of cancer in the future. purpose: this study is collecting and storing samples of blood from patients with pancreatic cancer and healthy participants.

objectives: * establish a central pancreatic cancer specimen (including serum and peripheral blood lymphocytes) repository to serve as a resource for current or future scientific studies. * utilize the clinical database to perform clinicopathologic correlation with the results of those studies. * test new hypotheses as they emerge. outline: this is a prospective study. blood is collected from patients with pancreatic cancer at baseline and then every 3-6 months for up to 2 years. all other participants have blood collected at baseline and complete questionnaires at baseline and then every 3-6 months for up to 2 years. serum and peripheral blood lymphocytes obtained from the blood samples are frozen and stored. projected accrual: a total of 200 patients and 200 other participants will be accrued for this study.

Eligibility criteria:
disease characteristics: * meets 1 of the following criteria: * histologically confirmed pancreatic malignant neoplasm * serologically or image-confirmed diagnosis of pancreatitis or nonmalignant pancreatic disease * healthy, at-risk participant meeting the following criteria: * smoker, diabetic, and/or has a family history of pancreatic cancer * healthy participant (no history of cancer) patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: adenocarcinoma of the pancreas recurrent pancreatic cancer stage i pancreatic cancer stage ii pancreatic cancer stage iii pancreatic cancer stage iv pancreatic cancer
epidemiology of cardiovascular disease in elderly turkish population

Conditions: Cardiovascular Diseases

Summary: this study will compose a national database of cardiovascular diseases' risk factors, concomitant diseases and the drug usage among the elderly patients in turkey.


Eligibility criteria:
inclusion criteria: * patients signed patient informed sheet and informed consent form * patients ≥65 years old * patients followed-up cardiology clinics exclusion criteria: * patients under 65 years old

Keywords: turkey epidemiologic
effect of family-centered empowerment model

Conditions: Acute Myocardial Infarction: Rehabilitation Phase

Summary: the objective of this study was to evaluate the effectiveness of a fcem-focused hybrid cr program for survivors of myocardial infarction (mi). the study sought to compare the long-term impact of fcem-based intervention with a standard cr program in terms of mortality rates and different aspects of health related quality of life (hrqol), which includes soft outcomes such as levels of stress, anxiety, psychological distress, quality of life (qol), and hard outcomes such as the percentage of ejection fraction (ef), independent functioning, and functional exercise capacity status.

the investigators conducted a triple-blind randomized controlled clinical trial study in patients admitted for mi to the ccu of an academic teaching hospital from june 2012 to january 2023. the study was approved by the institutional investigative review board at tarbiat modares university and baqiyatallah university of medical sciences. patients were block randomized to receive either standard home cardiac rehabilitation (cr) or cr using the family-centered empowerment model (fcem) strategy. patients had not previously gone through cr programs. the difference between the two groups was not disclosed at any point. patients consented knowing that they would receive cardiac rehabilitation, but without knowing the details. patients and their designated family/friend were enrolled as a 'unit'. patient empowerment was measured with fcem questionnaires pre-intervention and post-intervention for a total of 9 assessments. quality-of-life, perceived stress, state and trait anxiety, psychological distress, independent functioning, and functional exercise capacity status were assessed using the 36-item short form health survey (sf-36), the 14-item perceived stress, the 20-item state and 20-item trait anxiety questionnaires, kessler psychological distress scale,barthel index (bi) activities of daily living index, six-minute walk test (6mwt), and free walking index (fwi), respectively. in addition, echocardiography was used to measure ejection fraction.

Eligibility criteria:
inclusion criteria: * being within the age-range of 45 to 85 years old * having the minimum literacy for reading and writing * being hospitalized due to mi for the first time * verification of mi by clinical symptoms * enzyme-serum tests and cardiograph changes * lack of participation in the any related educational course simultaneously with the execution of intervention * patients' willingness toward participating in the research * having no psychological problems * ability to fill out the questionnaire and participating in the empowerment program. exclusion criteria: * any offending items from mentioned criteria.

Keywords: family-centered empowerment model quality of life perceived stress anxiety myocardial infarction clinical trial iran
impact of tegaderm hp and chg in major catheter related infections and dressing detachment

Conditions: Catheter-Related Infections

Summary: catheter related infection is a frequent and life threatening event in icu. a chlorhexidine impregnated sponge has been proven to reduce the rate of major catheter related infections in icu patients (hr=0.39, p=0.03) (timsit jama 2009). however, dressings are detached in 40% of cases before planned changes and the rate of unplanned dressing is significantly associated with the major catheter related infections. primary objective: to demonstrate that tegaderm chg, a new chg impregnated dressing decrease the rate of major catheter related infection as compared to non impregnated dressings and to demonstrate that highly adhesive dressing decrease the rate of detached dressings. secondary objectives: * to demonstrate that the use of high performance dressing decrease the rate of unstuck dressing and the rate of catheter infections. * to evaluate the tolerance of chg impregnated gel dressings (tegaderm chg). * to calculate the cost saving of each dressings

inclusion criteria: patients older than 18 years old with central venous who need a central vein and/or an arterial catheter for an expected duration of more than 48 hours.

Eligibility criteria:
inclusion criteria: * patients older than 18 years old with a central venous catheter or arterial catheter installed in the study departement for a maximum for 24 hours exclusion criteria: * pulmonary arterial catheter * antiseptic-impregnated catheter * hemodialysis catheter * chlorhexidine allergy * emergency catheter without surgical asepsis

Keywords: catheter dressing chlorhexidine patient admitted in icu with a cvc or art. catheter
immunohistochemical study of chordomas to improve their diagnosis and prognosis care

Conditions: Chordoma

Summary: chordomas are very rare malignant tumors, chemo-resistant with high propensity for recurrence. the role of immunotherapy in these patients remains largely unexplored while pd-l1 and cd8 status in the micro-environment of chordomas is basically not known. similarly, this tumor often poses diagnostic difficulties due to its resemblance with metastasis or chondrosarcoma, thus, it would be useful to know the expression status of factors used during the work-up of metastatic or mesenchymal tumors, like cdx2, insm1 and foxa1, which remains unknown for chordomas. thus, the aim of the study is to explore pd-l1, cd8, cdx2, insm1 and foxa1 expression in a series of chordomas and compare it with clinico-pathological and prognostic features.

retrospective, non-interventional study. a series of chordomas will be analyzed for detailed histologic features and for various immunohistochemical factors and results will be compared with clinical factors, like overall and disease-free survival.

Eligibility criteria:
inclusion criteria: * patients diagnosed with chordoma * sufficient histological material available * tumor expression of brachyury exclusion criteria: - insufficient histological material

Keywords: immunohistochemical pd-l1 cd8 cdx2 insm1 foxa1
radial extracorporeal shockwave therapy combined with evidence-based physical therapy for adhesive capsulitis

Conditions: Adhesive Capsulitis of Shoulder

Summary: the goal of this clinical trial is to evaluate the combined effects of radial extracorporeal shockwave therapy (reswt) and evidence-based physical therapy (ebpt) interventions for patients with adhesive capsulitis. the main questions it aims to answer are: what is the effectiveness of combining reswt with ebpt interventions for the management of adhesive capsulitis compared to ebpt alone? how does the combination of reswt and ebpt affect pain, range of motion, and functional outcomes in patients with adhesive capsulitis? researchers will compare reswt plus ebpt to a sham reswt plus ebpt to see if reswt provides better results for subjects with adhesive capsulitis. the study will randomly assign participants to receive either reswt plus ebpt or sham reswt plus ebpt over a 6-week intervention period. the primary outcomes will be pain and disability, while secondary outcomes will include shoulder range of motion, psychological distress, and health-related quality of life. these outcomes will be assessed at baseline, post-intervention, and 12 weeks post-randomization.


Eligibility criteria:
inclusion criteria: * having a relapsed or episode of pain score ≥5 at the assessment with a past history of pain for at least 2 weeks. * phase 1 or 2 frozen shoulder confirmed by a physician * rom restriction (\>75% rom loss in ≥2 directions including abduction, flexion and external rotation) * no treatment other than analgesics with unresponsive rom restriction for the past 2 months * unwilling or waiting and did not undergo joint injection * diagnosed with shoulder adhesive capsulitis, * ≥18 years * diabetes mellitus exclusion criteria: * bilateral shoulder involvement * history of previous surgery on the shoulder * shoulder fracture * cancer * glenohumeral or acromioclavicular arthritis * inflammatory disorders * bleeding disorders * presence of severe osteoporosis * pulmonary diseases * any neuromuscular disorders * pregnancy * implanted pacemaker

Keywords: frozen shoulder extracorporeal shockwave therapy
the comparison the cmv infection and reactivation after allogeneic hematopoietic stem cell transplantation between standard regimen, methotrexate plus cyclosporin a, and post-transplant cyclophosphamide-based regimen

Conditions: CMV Infection or Reactivation After Allogenic HSCT

Summary: the goal of this observational study is to compare the cmv infection and reactivation after allogeneic hematopoietic stem cell transplantation between standard regimen, methotrexate plus cyclosporin a, and post-transplant cyclophosphamide-based regimen. the main questions it aims to answer are: * how do cmv infection and reactivation differ between allo-sct patients who received a standard regimen versus those who received a post-transplant cyclophosphamide-based regimen? * progression-free survival, median overall survival, cumulative incidence of relapse, non-relapsed mortality (nrm) and gvhd at 2 years after allo-sct * the impact of cmv infection and cmv reactivation on progression-free survival, overall survival, and nrm * averse events of gvhd prophylaxis medication participants will be collected the data of treatment and treatment response during transplant until 2 years after transplant from hospital medical record.


Eligibility criteria:
inclusion criteria: * age more than 15 years * diagnosis of acute myeloid leukemia (aml), acute lymphoblastic leukemia (all), chronic myeloid leukemia (cml), chronic lymphocytic leukemia (cll), chronic myelomonocytic leukemia (cmml), myelodysplastic syndrome (mds), myelofibrosis primary and/or post pv/et myelofibrosis, aplastic anemia, lymphoma, or paroxysmal nocturnal hemoglobinuria * received hla-matched related (msd-hsct) or unrelated allo-sct (mud-hsct) or haploidentical hematopoietic stem cell transplantation exclusion criteria: * insufficient data needed for analysis

Keywords: cmv infection cmv reactivation allogenic hsct gvhd prophylaxis posttransplant cyclophosphamide (ptcy) cyclosporin a methotrexate
establishment of risk indicators and early warning system in infection patients

Conditions: Infections

Summary: serious infections refer to life-threatening infections with a morbidity and mortality rate of up to 50%, and are the main cause of death in critically ill patients, mainly including systemic inflammatory response syndrome, sepsis, infectious shock, or systemic multiple organ dysfunction syndrome. patients with severe infections have rapid disease development, which can cause disorders of cellular circulation and metabolism and impairment of multi-organ function in the early stage, mostly accompanied by clinical complications, and despite the progress of medical technology and the popularization of antibiotic application, the mortality and disability rate is high, which is a hot spot of clinical research today. patients with severe infections are exposed to a wide range of medical risk factors, including patient factors (advanced age, frailty, malnutrition, long hospital stay, prolonged bed rest), disease factors (immune deficiency, malignancy, diabetes, renal failure, liver failure), drug factors (long-term use of steroid hormones, chemotherapeutic drugs, nsaids, etc.), interventional factors (central venous catheter, recent invasive surgery, hemodialysis, endotracheal intubation or mechanical ventilation, etc.), which bring great challenges to clinical treatment. therefore, early identification of risk indicators for deterioration of infected patients provides a strategic basis for the medical team to take early warning measures to prevent deterioration and poor prognosis, and to reduce the risk of deterioration of patients, which is also the key to reduce the risk of death of infected patients.


Eligibility criteria:
inclusion criteria: * patients diagnosed with infection exclusion criteria: * case information is incomplete * do not accept follow-up
home tele-monitoring of non-invasive ventilation in copd patients in france

Conditions: Chronic Obstructive Pulmonary Disease

Summary: tele-monitoring emerged and unfolded differently among various healthcare organisations and countries. evidence regarding its impact on the management of copd patients is still insufficient to draw firm conclusions. assumption has been made that remote monitoring of home niv treatment could help to identify novel predictors of the early detection of niv failure and deteriorations in patients with copd. the incidence in routine clinical care of unplanned all-cause and copd-caused hospitalisations in patients treated with niv therapy who are continuously monitored by telemetric data in france needs evaluation. in addition, predictors of unplanned all-cause and copd-caused hospitalisations as well as of compliance and persistence to niv therapy should be assessed in this patient population with special respect to continuous tele-monitoring. the study will determine in france the incidence in routine clinical care of unplanned all-cause and copd-caused hospitalisations in patients treated with niv therapy who are continuously monitored by telemetric data. clinical and telemetric predictors of unplanned all-cause and copd-caused hospitalisations and of niv therapy compliance and persistence will be assessed in those patients


Eligibility criteria:
inclusion criteria: * age ≥18 years * copd eligible for niv treatment * prescription of an adequate resmed niv device with tele-monitoring option as part of routine clinical care * acceptance of tele-monitoring and corresponding data handling * naive to long-term niv treatment with initiation of niv either ≤7 days before or after enrolment into study * able to fully understand information on data protection and provide written informed consent for use of corresponding medical and telemetric data. exclusion criteria: * invasive ventilation therapy * another life-threatening disease with estimated survival \< 12 months (other than copd, e.g. cancer) * further exclusion criteria according to manua of the device intended and prescribed

Keywords: non invasive ventilation telemonitoring
adiponectin and circulating macrophage phenotypes in non-alcoholic fatty liver disease (nafld)

Conditions: Non-alcoholic Fatty Liver Disease

Summary: in peripheral blood; monocytes and macrophages are found in two phenotype; proinflammatory m1 and anti-inflammatory m2 phenotypes. m2 form is converted (or polarized) to m1 phenotype in various metabolic disorders such as obesity and type 2 diabetes mellitus.

in peripheral blood; monocytes and macrophages are found in two phenotype; proinflammatory m1 and anti-inflammatory m2 phenotypes. m2 form is converted (or polarized) to m1 phenotype in various metabolic disorders such as obesity and type 2 diabetes mellitus. in addition, these forms also are related to insulin resistance and inflammation in adipose tissue. today, there is no study that investigate the role of adiponectin an anti-inflammatory adipokine, on macrophage polarization in non-alcoholic fatty liver disease.

Eligibility criteria:
inclusion criteria: * persistently (at least 6 months) elevated aminotransferases * ultrasonographic presence of bright liver without any other liver or biliary tract disease * liver histology compatible with a diagnosis of nash or ss exclusion criteria: * a history of alcohol consumption \>40 g/wk, as assessed by a detailed interview extended to family members * morbid obesity \[body mass index (bmi) ≥40 kg/m2\], hypertension * positive blood markers of viral, autoimmune, or celiac disease * abnormal copper metabolism or thyroid function tests * a diagnosis of t2dm and systemic arterial hypertension * total cholesterol (tc) ≥250 mg/dl, triglycerides (tg) ≥400 mg/dl, exposure to occupational hepatotoxins or drugs known to affect glucose and lipid metabolism
early identification and effective management of pediatric sepsis

Conditions: Severe Sepsis; Sepsis; Septic Shock

Summary: in patients diagnosed as sepsis on picu admission, early and accurate identification of patients who will develop organ dysfunction (severe sepsis) is critical for effective management and positive outcome. a multiple marker approach would improve clinical utility compared with use of a single marker. the primary goal of this part of study is to define a combination of multiple markers, derived from novel biomarkers (ncd-64, il-27, strem, hla-dr, il-10), metabolomics and routine clinical parameters, which could predict severe sepsis and determine the severity of disease.

we intend to enroll pediatric sepsis patients at four picus and divide them into two groups based on clinical outcomes: severe sepsis group (patients who progress into severe sepsis), sepsis group (patients who do not progress in to severe sepsis). we intend to perform predictive modeling using multivariable analyses of the novel biomarkers and derive a biomarker panel and algorithm for early diagnosis of severe sepsis. the predictive value of the biomarker panel for early identification of severe sepsis will be compared with established indices, such as prism iii and psofa score.

Eligibility criteria:
inclusion criteria: * the presence of at least two of the following four criteria, one of which must be abnormal temperature or leukocyte count: * coreb temperature of \>38.5°c or \<36°c. * tachycardia, defined as a mean heart rate \>2 sd above normal for age in the absence of external stimulus, chronic drugs, or painful stimuli; or otherwise unexplained persistent elevation over a 0.5- to 4-hr time period or for children \<1 yr old: bradycardia, defined as a mean heart rate \<10th percentile for age in the absence of external vagal stimulus, β-blocker drugs, or congenital heart disease; or otherwise unexplained persistent depression over a 0.5-hr time period. * mean respiratory rate \>2 sd above normal for age or mechanical ventilation for an acute process not related to underlying neuromuscular disease or the receipt of general anesthesia. * leukocyte count elevated or depressed for age (not secondary to chemotherapy-induced leukopenia) or \>10% immature neutrophils * a suspected or proven (by positive culture, tissue stain, or polymerase chain reaction test) infection caused by any pathogen or a clinical syndrome associated with a high probability of infection. evidence of infection includes positive findings on clinical exam, imaging, or laboratory tests exclusion criteria: * patients without informed consent * discharge within 48 hours

Keywords: metabolomics biomarkers inflammatory mediator profile mods predictive model